Sponsored content. This post is sponsored by GlaxoSmithKline, and is written by Luke Devey.
It’s been nine months since I made the transition from clinical academia to GSK via the Esprit R&D leadership development programme. Making the move was a tough decision and my previous blog captured just my first impressions. So how do I feel now that the initial shock has subsided?
Breadth of opportunity
During my first role in Esprit, working as a physician scientist in the Experimental Medicine Unit, I’ve been exposed to an almost overwhelming breadth of opportunities, ranging from leading a team developing a novel immunotherapeutic to running clinical studies and participating in commercial boards and business development. I’ve found the organisation to be like a sweet shop of novel biology and exciting technologies, many of which have transformative potential. Of the areas I’ve needed to learn about, some have been completely unanticipated. Who knew that I would be expected to contribute to discussions of manufacturing design, assay validation or Bayesian statistics? As a result, I liken a day at GSK to a workout at an intellectual gym, and it’s hugely enjoyable. Continue reading

